A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias

Trial Profile

A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Pfizer; Wyeth Pharmaceuticals
  • Most Recent Events

    • 12 Dec 2017 Long-term results of cardiac, vascular and hypertensive safety of bosutinib from parent and extension studies presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 26 Oct 2017 Results (n=403) assessing long term safety and efficacy published in the Cancer.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top